© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo AMGN -2.85% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully to:
+ Add another position Close JNJ +0.89% Add to/Remove from Watchlist Add to Watchlist Add Position
Position added successfully to:
+ Add another position Close
(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Amgen (NASDAQ:AMGN)'s biosimilar version of Johnson & Johnson (NYSE:JNJ)'s blockbuster psoriasis treatment, Stelara, for multiple inflammatory diseases.
Despite the FDA approval, Amgen's treatment is expected to be launched in 2025 as part of a legal settlement between the two companies earlier this year to delay the entry of the therapy.
Biosimilars are close copies of complex biological drugs.
Stelara, introduced in 2009, has been J&J's top-selling drug since 2019, with sales reaching $9.7 billion in 2022.
U.S. FDA approves Amgen's biosimilar version of J&J's psoriasis drug Recommended
Carlsberg warns weak consumer sentiment may hurt beer sales in Europe, Southeast Asia
Police to treat shoplifting like organised crime
Nokia to axe up to 14,000 jobs to cut costs
X social media to test $1 subscription for posting content, like, reply
Dow futures move higher, earnings in focus